3.3. Effect of MED-01 on the Nugent Score and Vaginal pH 
Changes in the Nugent score after 12 weeks of MED-01 intake were analyzed as a primary outcome. The Nugent score in the MED-01-intake group decreased by −0.36 ± 1.72, whereas it increased by 0.19 ± 1.85 in the placebo-intake group, showing a statistically significant difference between the two groups (Among the total subjects (Nugent score 4-6), 10 subjects (25.6%) in the MED-01 group improved to a normal score (0–3), which is twice that of 5 subjects (13.5%) in the placebo group. On the other hand, the number of subjects whose Nugent score rose to the BV stage was 6 (15.4%) and 8 (21.6%), respectively. However, there was no statistical significance between groups (